# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell pr...
HC Wainwright & Co. analyst Yi Chen maintains BioLife Solutions (NASDAQ:BLFS) with a Buy and raises the price target fro...
BioLife Solutions (NASDAQ:BLFS) raises FY2025 sales outlook from $95.500 million-$99.000 million to $100.000 million-$103.000 m...
BioLife Solns (NASDAQ:BLFS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04)...
BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and...
HC Wainwright & Co. analyst Yi Chen reiterates BioLife Solutions (NASDAQ:BLFS) with a Buy and maintains $30 price target.
BioLife Solutions (NASDAQ:BLFS) affirms FY2025 sales outlook from $95.50 million-$99.00 million to $95.50 million-$99.00 millio...